Forefront Analytics’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Forefront Analytics’s Portfolio CDAK Stock Details CDAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-110,210	Closed	-$19.2K	–	80
2023 Q1	$19.2K	Buy	110,210 +10,275	+10%	+$5.72K	0.01%	79
2022 Q4	$39.7K	Buy	99,935 +43,450	+77%	+$28.6K	0.02%	70
2022 Q3	$47K	Buy	56,485 +38,175	+208%	+$80.1K	0.03%	64
2022 Q2	$57K	Sell	18,310 -1,000	-5%	-$3.51K	0.03%	63
2022 Q1	$122K	Buy	+19,310	New	+$121K	0.05%	57

Forefront Analytics's CDAK Position: Q2 2023 in Review

Forefront Analytics sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2023, closing a stake of 110,210 shares — an estimated $19.2K sold.

Forefront Analytics first reported a position in CDAK in Q1 2022 and held it in 5 quarters. The position peaked at $122K in Q1 2022. 1 fund tracked by Wall St. Rank holds CDAK as of Q2 2023.

Forefront Analytics reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Forefront Analytics sold 110,210 Codiak BioSciences, Inc. Common Stock shares in Q2 2023, an estimated $19.2K.
Forefront Analytics first reported a position in Codiak BioSciences, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Forefront Analytics's Codiak BioSciences, Inc. Common Stock position peaked at $122K in Q1 2022.
1 fund tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2023.

Based on Forefront Analytics's 13F filing for Q2 2023, filed 11 Aug 2023.